SCHEMBL6285264

SCHEMBL6285264

CC(C)(C)OC(=O)NCc1cccc(F)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.56
CTSK P43235 1/20 0.56
GLS O94925 3/20 0.51
EPHX2 P34913 1/20 0.50
SRC P12931 1/20 0.49
GRM2 Q14416 1/20 0.48
RAB9A P51151 2/20 0.48
MAPK1 P28482 1/20 0.48
KDM4A O75164 1/20 0.48
BRD4 O60885 2/20 0.47
ANPEP P15144 1/20 0.47
LMNA P02545 1/20 0.47
TSHR P16473 1/20 0.47
PPARG P37231 1/20 0.47
NCOA2 Q15596 1/20 0.47
NCOA1 Q15788 1/20 0.47
NCOA3 Q9Y6Q9 1/20 0.47
CREBBP Q92793 1/20 0.47
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31456961 1.00 CTSS (0.56) CTSSCTSKGLSEPHX2SRC
SCHEMBL18198086 0.88 CTSS (0.54) CTSSCTSKEPHX2RAB9AMAPK1
SCHEMBL5729170 0.86 CTSS (0.54) CTSSCTSKLMNATSHRPPARG
SCHEMBL10774088 0.86 CTSS (0.51) CTSSCTSKRAB9AMAPK1LMNA
SCHEMBL4218290 0.85 GLS (0.54) GLSGRM2KDM4ABRD4CREBBP
SCHEMBL15370948 0.85 GLS (0.51) CTSSCTSKGLSKDM4ABRD4
SCHEMBL18664572 0.85 GRM2 (0.54) CTSSCTSKGLSSRCGRM2
SCHEMBL15163979 0.85 GRM2 (0.52) CTSSCTSKGLSGRM2RAB9A
SCHEMBL12791343 0.84 GRM2 (0.46) CTSSCTSKGLSGRM2KDM4A
SCHEMBL16181822 0.84 GLS (0.55) CTSSCTSKGLSKDM4ABRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103038221-A Chk-1 activity regulator SENTINEL ONCOLOGY LTD 2013-04-10 CN disclosed
US-6894050-B2 5-HT receptor ligands and uses thereof PFIZER INC. (US) 2005-05-17 US disclosed
US-20050090503-A1 5-HT receptor ligands and uses thereof PFIZER INC 2005-04-28 US disclosed
US-20050020604-A1 5-HT receptor ligands and uses thereof PFIZER INC 2005-01-27 US disclosed
EP-1401820-A1 5-HT RECEPTOR LIGANDS AND USES THEREOF Pfizer Products Inc. (US) 2004-03-31 EP disclosed
US-20030125334-A1 5-HT receptor ligands and uses thereof CHIANG PHOEBE (US) 2003-07-03 US disclosed
WO-2003000666-A1 5-HT RECEPTOR LIGANDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090503-A1 5-HT receptor ligands and uses thereof HTR2A, HTR1A, HTR5A CTSS 3016/4885CTSK 3083/4885GLS 656/4885
US-20050020604-A1 5-HT receptor ligands and uses thereof HTR2A, HTR1A, HTR5A CTSS 3016/4885CTSK 3083/4885GLS 656/4885
US-20030125334-A1 5-HT receptor ligands and uses thereof HTR1A, HTR2A, HTR5A CTSS 3051/4885CTSK 2957/4885GLS 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.